Apollo Medical Holdings (“ApolloMed” or “AMEH”) is a leading population management and physician healthcare delivery company. Apollo provides medical management and care coordination for over 1,000 providers and 40,000 patients; including many senior patients. In addition, Apollo doctors provide care for over 100,000 patients in hospitals, facilities, and clinics. ApolloMed’s integrated healthcare delivery platform is comprised of ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group IPA (Independent Physician Association), Apollo Palliative Services, and ApolloMed Care Clinics. ApolloMed is able to provide high quality, cost-effective care, and its revenue model ranges from traditional volume-based payments to taking full clinical and financial risk for pools of patients.

1. Integrated Healthcare for Better Patient Outcomes
Apollo Medical Holdings, Inc.
Investor Presentation
Aug 2015

2. Safe Harbor Statement
This presentation may contain forward-looking statements, including information about management's view of
Apollo Medical Holdings, Inc. (“the Company”) future expectations, plans and prospects. In particular, when used
in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar
conditional expressions are intended to identify forward-looking statements. Any statements made in this
presentation other than those of historical fact, about an action, event or development, are forward-looking
statements. These statements involve known and unknown risks, uncertainties and other factors, which may
cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or
implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the
Company’s future results. The forward-looking statements included in this presentation are made only as of the
date hereof. The Company cannot guarantee future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally,
the Company undertakes no obligation to update these statements after the date of this release, except as
required by law, and also takes no obligation to update or correct information prepared by third parties that are
not paid for by Apollo Medical Holdings, Inc.
2

3. Summary
 An integrated, physician driven, population healthcare management company
 Medical Management, Care Coordination and Physician Care for 100,000+ people
 Nearly 200% year-over-year revenue growth; majority organic and recurring
 $33.0 Million FY 2015 vs. $11.2 Million in FY 2014; EBITDA positive in Fiscal Year and Q4 2015
 Trailing twelve months revenue of nearly $40M (Market Cap less than 1X revenue at approx. $38M)
 One of few small cap public companies in attractive healthcare services sector
 Increasing flow of investment capital into sector, robust M&A valuations and IPOs
 Recent IPOs of Evolent Health and acquisition of IPCM indicate market valuation
 Fresenius Medical Care invested $12 Million in March 2014
 Growth strategy to include geographic expansion and acquisitions of platform
3

4. Equity Overview
 OTC: AMEH (NASDAQ Uplist Pending Approval)
 Outstanding Shares: 4.9 Million
 Recent Price: $8.00
 52 week range: $4.50 - $10.00
 Market Capitalization: $38M
 Enterprise Value: $44M
 Price / Sales: <1.0 X ttm
 Fiscal Year ends March 31, 2015
4

5. ApolloMed Overview
Integrated physician healthcare services
 Population Health Management
 Management of complex, chronically ill patients
 Technology and data driven analytics
 Medical Management and Care Coordination
 Management of Total Cost of Care for population
 Direct Patient Care (augments population health mgt. and influences care)
 Inpatient Care: Hospitalists, Critical Care Specialists, Physician Advisors
 Outpatient Care: Primary Care Physicians, Specialists, Clinics, Home Health
5

6. Diversified Revenue
 Revenue from Hospitals, Health Plans, Medical Groups and Government
 Range of payments from Fee for Service (FFS) to Full Risk models
 Maverick is capitated entity paid monthly from Health Plan Premiums
 Scalable model with focus on growing integrated platform outside of California
 ApolloMed has 50+ different payors
6

7. 7
ApolloMed Model – Inpatient and Outpatient Care Driving Patient Outcomes
 ApolloMed ACO (709
exclusively signed
physicians & nearly
30,000 Medicare FFS
patients)
– Population
Management
– Care Coordination
 Maverick Medical
Group (IPA) (150+
PCP, 400+ specialists,
& 10,000+ patients )
– Capitated entity
– Provider and full
risk medical
management
 ApolloMed Hospital
Physician Services (70+
hospitalists serving 28+
facilities)
– Hospitalist and Physician
Advisory Services
– Post-acute services
 ApolloMed Care Clinics
 Primary Care
 Cardiovascular / Specialty
Care
 Palliative Care
 Home Health
 Hospice
CLINICALEXPERTISE

8. Industry Trends
 Government and private sector trend from FFS/volume to outcome driven
 Value based reimbursement, Bundled Payments, ACO, PTN
 Irrespective of politics, better care and lower cost goals will continue
 Transparency of information; by procedure, by physician, by hospital
 New physician driven models forming and gaining traction
 Physician and Patients are core of healthcare in emerging landscape
 By 2016, 85% of Medicare payments will be tied to quality and value
 By 2018, at least 50% of payments will be paid through “Alternative
payment models” , such as ACOs, PTNs, Bundled payments
 Consumers are becoming more engaged in their own care
 Exchanges, Rising Premiums, Social Media
8

9. Healthcare and Healthcare Delivery Market is Large and Growing
 Seniors are increasing in number and living longer
 76 Million baby boomers
 3.6 Million new Seniors every year
 US Healthcare market
 $2.8 Trillion in 2012
 Growing to nearly $4.8 Trillion by 2021
 50+% US spend is on Hospital and Physician Care
(Bio and IT only about 20% total)
 Healthcare is ~17% of US GDP heading to near 20%
of US GDP by 2021
 All signs point to increased market size and need to
optimize healthcare costs into the next decade
9

10. 10
Senior Market Growth is Significant

11. Apollo Differentiators
 Ability to not only manage, but impact care when needed most
 Expertise in providing high quality, cost efficient care
 Expertise in managing complex, chronically ill patients
 ApolloMed built on “emerging” trend of value based healthcare
 Data analytics; past, current and predictive (i.e. goal of “real time”)
 Population management and care coordination capabilities
 Ability to take performance risk for total patient care profitably; most critical
attribute inn new value based US healthcare system
11

12. Some detailed examples of the “Secret Sauce” – Network Building
 Network Providers (Maverick and ApolloMed ACO)
 Potential for higher revenue from additional patients through Apollo network
 Fixed rate PMPM and shared savings payment models (i.e. get paid for each patient)
 Access to “full picture of patients” through data and technology
 Assistance with coding and transition to value based care US Healthcare System
 Alternative for physicians to remain independent; not employed by hospital or health plan
 Staff Model Doctors
 Increased compensation
 Flexible scheduling (one week on/one week off)
 No billing or credentialing headaches, Malpractice Insurance, Hospital Privileges
12

13. 13
ApolloMed Hospitalist Impact
Significant Outperformance - Sample Hospitalization Utilization Metrics
3.3
6.8
6.1%
18.0%
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
ApolloMed
Medicare LOS
Medical Staff
Medicare LOS
ApolloMed
Medi-Cal
Denial Rate
Medical Staff
Denial Rate
Medicare Average LOS*
733
864
1,706
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
ApolloMed DaVita HCP Medicare FFS
Senior Inpatient Bed Days/1,000
Patients
*LOS=length of stay; Performance Year 1= July 2012 to December 2013
687
543
0
500
1000
Benchmark Performance Year 1*
ApolloMed ACO Hospitalization
Rate per 1,000

14. 14
Significant Outperformance - Sample Hospitalization Utilization Metrics
189
258
302
0
50
100
150
200
250
300
350
Maverick IPA California National
Senior Admits/1,000
230
195
170
180
190
200
210
220
230
240
Benchmark Performance Year 1
ApolloMed ACO 30-Day All-
Cause Readmission per 1,000
Discharges
78.4%
86.3%
74%
76%
78%
80%
82%
84%
86%
88%
Maverick IPA National
Senior Medical Loss Ratio
(MLR)

15. Network Building is growing and starting to impact financials …
15
PY1 PY2
48
175
400
0
100
200
300
400
500
Number of Maverick Doctors
130
709
0
100
200
300
400
500
600
700
800
Number of ACO Doctors
2012 2013 2014
PY1 PY2
0
5,000
10,000
0
2,000
4,000
6,000
8,000
10,000
12,000
Number of Maverick Patients
2012 2013 2014
10,200
30,000
0
10,000
20,000
30,000
40,000
Number of ACO Patients

16. 16
… as revenue has jumped nearly 200% Y/Y and quarterly growth achieved
0
5
10
15
20
25
30
35
FY2013 FY2014 FY2015
Apollo Annual Revenue
Apollo Annual Revenue
Note: Fiscal year 2015 is from April 1, 2014 to March 31st, 2015
$33 Million

17. Income Statement and Balance Sheet Summary
 FY 2015 revenue of $33.0M vs. $11.2M Y/Y (195% gain)
 Nearly 70% of this growth is organic and recurring
 Emphasis on Maverick IPA, ACO and acquisition growth
 FY 2015 Net Loss of ($.7M) vs. ($4.4M) in FY 2014
 Loss improvement while making infrastructure investments
 FY 2015 EBITDA of $467K and Gross Profit Margin of 33%
 Operating businesses generating cash
 Q4 2015 revenue increase of $9.6M from $3.2M; 200% gain
 Total Assets of $15.0M and Cash/Equivalents of $5.0M
17

18. Business Strategy
 Scale current businesses in California
 Establish and grow networks outside of California leveraging
clinical know how and technology
 Emphasize Population Management Growth
 Focus on strategic acquisitions in attractive geographies
 Continue to scale infrastructure including centralized data
analytics and “real-time” technology advances
 Continue to assume and manage medical and financial risk
18

19.  More than 20 years in managed care industry
 Previously COO of Prospect Medical Group, managing over 250,000
patients in 13 IPAs. Former Regional Vice President of Cigna Health Plan
 Co-founder
 Medical degree from the University of California, Irvine
 Diplomate of the American Board of Internal Medicine
 Early partner of HealthCare Partners (acquired by DaVita).
 Visionary in the fields of Palliative Care and Hospital-at-Home Care
 30 year veteran in the field
 Appointed CFO in May 2014. Director since 2012.
 Former CEO of USC University Hospital and USC/Norris Cancer Center;
former CFO and Vice Chancellor of UCLA Medical Center; former CFO of
Beth Israel Deaconess Medical Center and Tufts University Medical Center.
 Co-founder
 Medical degree from the Georgetown University School of Medicine and
completed Residency in Internal Medicine at USC
Our Leadership
Warren Hosseinion, M.D.
CEO & Director
Mitchell Creem
CFO & Director
Liviu Chindris, M.D
President of Apollo Palliative Services
Adrian Vazquez, M.D.
Chief Medical Officer
Mark Marten
President, Maverick Medical Group
19

20.  CEO of SCAN, 10th largest MA plan in the U.S.
 Expertise in Government relations, Knox Kneene and Healthcare IT
 CEO of Appzure, Inc.
 Founder and CEO of Accelerated Networks, which he took public on the
NASDAQ in 2000.
 37 years in private and public healthcare sectors
 CEO of USC University Hospital and USC/Norris Cancer Hospital
 Former Senior Vice President of Operations for Tenet
Board of Directors
 Strategy, Capital, M&A, and Corporate Development for ApolloMed (FT role)
 Served as CEO, Corp Dev/M&A, Consultant roles with S&P 500 (Prudential
Healthcare, Fluor, Fed Ex ) and growth healthcare and technology companies
Gary Augusta
Executive Chairman
Ted Schreck
Director
Suresh Nihalani
Director
David Schmidt
Director
Warren Hosseinion, M.D.
CEO & Director
 Founder and managing partner of SEC Law Firm in Los Angeles.
 Over 25 years of experience in public and private securities offerings, IPOs,
SEC reporting, corporate governance and M&A. Has given testimony to the
SEC’s Advisory Committee of the American Bar Association. J.D. from NYU.
Lance Kimmel
Director
Mitchell Creem
CFO & Director
20

21. Valuations are robust and accelerating for value based, risk taking models
 Evolent (NYSE: EVH) – IPO June 5th
 Population Management and Value Based Care Offerings
 $1+B valuation on $100M revenues with operating losses (S1 data)
 OSCAR
 Valued at $1.5 Billion with 40,000 risk lives and $200M revenue
 NY/NJ focus with Goldman Sachs investment
 Humana and Health Net Acquisitions
 Large Equity gains and potential for more M&A (Pop Mgt. and Risk rationale)
 Hospitalist/ER and Integrated Care Companies
 Davita/HCP merger and Team Health (TMH)/IPC (IPCM) merger as examples
 Valued around 1.5X-2.5X ttm revenues and 10X to 20+X EBITDA multiples
21

22. AMEH Shareholder Overview
 OTC: AMEH (NASDAQ Uplist Pending Approval)
 Outstanding Shares: 4.9 Million
 Recent Price: $8.00
 52 week range: $4.50 - $10.00
 Market Capitalization: $38M
 Enterprise Value: $44M
 Price / Sales: <1.0 X ttm
 Fiscal Year ends March 31, 2015
22